BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabrizi F, Messa P. Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 2018;11:1135-42. [PMID: 30309263 DOI: 10.1080/17512433.2018.1534202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Mailly L, Baumert TF. Hepatitis C virus infection and tight junction proteins: The ties that bind. Biochim Biophys Acta Biomembr 2020;1862:183296. [PMID: 32268133 DOI: 10.1016/j.bbamem.2020.183296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Alfano G, Guaraldi G, Fontana F, Bellasi A, Cappelli G. Therapeutic management of HIV-infected patients with chronic kidney disease. J Nephrol 2020;33:699-713. [PMID: 32020538 DOI: 10.1007/s40620-020-00701-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Boff da Costa R, Boff Costa M, Longo L, Miotto DE, Hirata Dellavia G, Trucollo Michalczuk M, Reis Álvares-da-Silva M. Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications. PLoS One 2021;16:e0245767. [PMID: 33577593 DOI: 10.1371/journal.pone.0245767] [Reference Citation Analysis]